IRX-2: Clinical Trials

3 trials of IRX-2, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed, 1 withdrawn. 3 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Active not recruiting 1, Completed 1, Withdrawn 1
Phase 21Completed 1

Follow IRX-2: new trials by email Literature Review of IRX-2 trials Research Report on IRX-2

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
Cyclophosphamide, IRX-2, Nivolumab - Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Phase 1WithdrawnEmory University2020-07-012019-08-28
IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer
Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Nivolumab - Recurrent Hepatocellular Carcinoma, Refractory Liver Carcinoma
Phase 1Active not recruitingCity of Hope Medical Center82019-05-172026-08-21
IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer
Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Pembrolizumab - Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Phase 1 / Phase 2CompletedCity of Hope Medical Center92019-04-302026-10-21

Conditions studied

Carcinoma, Hepatocellular (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Sponsors

City of Hope Medical Center (2)  ·  Emory University (1)

Countries

United States (3)

Top investigators

Daneng Li (1)  ·  Joseph Chao (1)  ·  Mihir Patel, MD (1)

NIH funding

P30CA033572 (1)